Aims We examined the efficacy and safety of dapagliflozin, compared with placebo, according to aetiology in patients with heart failure (HF) with reduced ejection fraction …
ME Nassif, SL Windsor, K Gosch… - Circulation: Heart …, 2023 - Am Heart Assoc
BACKGROUND: Patients with heart failure (HF) have a high burden of symptoms and physical limitations, regardless of ejection fraction (EF). Whether the benefits of SGLT2 …
Background: Goals of management in patients with heart failure and reduced ejection fraction include reducing death and hospitalizations, and improving health status …
JW Ostrominski, M Vaduganathan… - European Journal of …, 2022 - Wiley Online Library
Aims This pre‐specified analysis of the DELIVER trial examined whether clinical benefits of dapagliflozin in heart failure (HF) with left ventricular ejection fraction (LVEF)> 40% varied by …
Importance Dapagliflozin has been shown to reduce the risk of cardiovascular death or worsening heart failure (HF) in patients with chronic HF and reduced ejection fraction …
Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure and cardiovascular death among patients with chronic heart …
KF Docherty, PS Jhund, I Anand, O Bengtsson… - Circulation, 2020 - Am Heart Assoc
Background: In the DAPA-HF trial (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure), dapagliflozin, added to guideline-recommended therapies, reduced the risk …
Importance Additional treatments are needed for heart failure with reduced ejection fraction (HFrEF). Sodium-glucose cotransporter 2 (SGLT2) inhibitors may be an effective treatment …
Importance Sodium-glucose cotransporter 2 inhibitors are known to reduce heart failure events and slow progression of kidney disease among patients with heart failure and a …